TSRL, Inc

TSRL, Inc. is a privately owned preclinical accelerator located in Ann Arbor, Michigan, specializing in the advancement of promising therapeutics for treating severe and multidrug-resistant infections. The company's 7,200 square foot facility features 5,000 square feet of wet lab space, equipped for analytical chemistry, formulation, cell culture, and in vivo testing.

Focused on co-developing technologies through academic partnerships, TSRL, Inc. provides infrastructure, expertise, and access to non-dilutive funding to advance its lead candidates into clinical development. The company has recently been awarded multiple grants to support the development of innovative therapies, including a first-in-class oral antibiotic and a novel heparin reversal therapy.

Generated from the website